

Global Cystic Fibrosis Therapeutics Market Outlook 2022

<https://marketpublishers.com/r/G9460E90A15EN.html>

Date: July 2017

Pages: 140

Price: US\$ 3,000.00 (Single User License)

ID: G9460E90A15EN

Abstracts

The Global Cystic Fibrosis Therapeutics industry has reported a tremendous growth in the recent years, and is presenting ample opportunities to the industry players. With improving life expectancy and rising awareness, the global cystic fibrosis therapeutics market is poised to scale newer acmes. Also, there lies enormous opportunity for industry participants to tap the fast growing market, which would garner huge revenue on the back of rising strategic consolidations and commercialization of the new drugs targeting the CFTR gene or protein.

The latest research by RNCOS titled, "Global Cystic Fibrosis Therapeutics Market Outlook 2022", unfolds the market dynamics of the cystic fibrosis therapeutics market. According to this new research report, the market for cystic fibrosis therapeutics was valued at US\$ 1.94 Billion in 2016.

The report showcases the segmentation of cystic fibrosis therapeutics market on the basis of the pharmacological class, mutation class, drug molecule type, and geographical penetration. It also provides an insight on the current market scenario, as well as forecasts of the aforementioned segments till 2022. The report provides an in-depth analysis of all the major segments, taking into account the major developments taking place at global level in the respective segments that will further boost the growth of cystic fibrosis therapeutics market.

Based on pharmacological class, the report broadly categorizes cystic fibrosis therapeutics market into Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators, Mucolytic agents, Pancreatic Enzymes products, Antibiotics, and Other therapies. CFTR modulators emerged as the major revenue earners of the industry, holding the largest share. This large share of the market is attributed to recent

market approvals of Kalydeco (ivacaftor) and Orkambi (lumacaftor and ivacaftor) for the treatment of patients with CF and robust pipeline.

Based on CF mutation class, the cystic fibrosis therapeutics market is further categorized into commercialized and non-commercialized mutation class specific therapies. CFTR mutation Class II accounted for largest share in the total cystic fibrosis therapeutics market in 2016.

Based on drug molecule type, the cystic fibrosis therapeutics market is further categorized into small molecule and biologic. The small molecule segment accounted for largest share in the total cystic fibrosis therapeutics market in 2016.

Additionally, the report covers the geographic analysis of the global cystic fibrosis therapeutics market by segmenting into three major geographic regions - North America, Europe, and Asia Pacific. North America is the largest market for cystic fibrosis. This high share is attributed to increasing awareness in the market, coupled with growing research initiatives. However, the European market is poised to witness the highest growth owing to increasing focus of players in this region.

Besides, the report covers the profiles of key players like Genentech, Inc. (A Member of the Roche Group), Novartis, Vertex Pharmaceuticals Incorporated, Abbott Laboratories, Gilead Sciences, Inc., Allergan plc, etc. with the key financials, providing a comprehensive outlook of global cystic fibrosis therapeutics industry. In addition, the report elucidates key developments of players related to cystic fibrosis industry. Overall, the report provides all the pre-requisite information for clients looking to venture in this industry, and facilitate them to formulate schemes while going for an investment/partnership in the industry.

Contents

1. ANALYST VIEW

2. RESEARCH METHODOLOGY

3. CYSTIC FIBROSIS: AN OVERVIEW

4. MARKET DYNAMICS

4.1 Drivers

- 4.1.1 Robust Pipeline
- 4.1.2 Rising Prevalence of Cystic Fibrosis
- 4.1.3 Rising Life expectancy of Cystic Fibrosis Patient's
- 4.1.4 Improvement in Diagnostic Technologies
- 4.1.5 Increasing Awareness
- 4.1.6 Unmet Medical Needs

4.2 Restraints

- 4.2.1 Cystic Fibrosis Related Complications
- 4.2.2 Increased Risk of Bacterial Infections in Cystic Fibrosis Patients
- 4.2.3 High Cost

4.3 Opportunities

- 4.3.1 Patent Expiry of Biggest-Selling Drugs
- 4.3.2 Gene Therapy Breakthrough for Cystic Fibrosis

5. GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET OUTLOOK 2022

6. MAJOR MARKETED PRODUCTS

- 6.1 Orkambi (lumacaftor/ivacaftor)
- 6.2 Kalydeco (Ivacaftor)
- 6.3 Cayston (Inhaled Aztreonam)
- 6.4 Pulmozyme (Dornase Alfa)
- 6.5 TOBI
- 6.6 Creon
- 6.7 Zenpep
- 6.8 Ventolin
- 6.9 Bronchitol (Inhaled Mannitol)
- 6.10 ADEKplusTM

6.11 Ibuprofen

7. MARKET SEGMENTATION BY PHARMACOLOGICAL CLASS

7.1 CFTR modulators

7.2 Mucolytic Agents

7.3 Pancreatic Enzyme Replacement Products

7.4 Antibiotics

7.5 Other Therapies

8. MARKET SEGMENTATION BY DRUG MOLECULE

8.1 Small Molecule

8.2 Biologic Drugs

9. MARKET SEGMENTATION BY CYSTIC FIBROSIS MUTATION TYPE

9.1 Commercialized

9.1.1 Class I

9.1.2 Class II

9.1.3 Class III

9.2 Non-Commercialized

9.2.1 Class IV

9.2.2 Class V

9.2.3 Class VI

10. MARKET SEGMENTATION BY GEOGRAPHY

10.1 North America

10.2 Europe

10.3 Asia Pacific

11. INDUSTRY TRENDS & DEVELOPMENTS

11.1 Genetic Testing

11.2 Technological Advances

11.3 CFTR Modulators - Gaining Momentum

11.4 Upsurge in the Number of Strategic Alliances

11.5 Combination Therapy

- 11.6 Co-pay and Assistance Programs by Vendors
- 11.7 Increased R&D Activities: Pillars for Market Growth

12. CYSTIC FIBROSIS PIPELINE ANALYSIS

- 12.1 Pipeline Analysis by Phase of Development
- 12.2 Pipeline Analysis by Key Players
- 12.3 Pipeline Analysis by Geography
- 12.4 Pipeline Analysis by Routes of Administration

13. PORTER'S FIVE FORCES ANALYSIS

14. COMPETITIVE LANDSCAPE

- 14.1 Share of Major Players

15. COMPANY PROFILES

- 15.1 Genentech, Inc. (A Member of the Roche Group)
- 15.2 Novartis
- 15.3 Vertex Pharmaceuticals Incorporated
- 15.4 Abbott Laboratories
- 15.5 Gilead Sciences, Inc.
- 15.6 Johnson & Johnson
- 15.7 Allergan plc
- 15.8 GlaxoSmithKline
- 15.9 Mylan N.V.
- 15.10 Pharmaxis Ltd

List Of Figures

LIST OF FIGURES:

Figure 4-1: %age of CF individuals over the age of

Figure 4-2: Estimated Prevalence of Cystic Fibrosis per 100,000 Habitants, 2015-2016

Figure 4-3: Effect of novel therapies on life expectancy of cystic fibrosis patients

Figure 5-1: Global – Cystic Fibrosis Therapeutics Market (Billion US\$), 2016-2022

Figure 6-1: Global - Sales of Orkambi (Million US\$), 2015 & 2016

Figure 6-2: Global - Sales of Kalydeco (Million US\$), 2012-2016

Figure 6-3: Global - Sales of Cayston (Million US\$), 2014-2016

Figure 6-4: Global - Sales of Pulmozyme (Million US\$), 2012-2016

Figure 6-5: Global - Sales of TOBI (Million US\$), 2014-2016

Figure 6-6: Global - Sales of Creon (Million US\$), 2014-2016

Figure 6-7: Global - Sales of Zenpep (Million US\$), 2014-2016

Figure 6-8: Global - Sales of Ventolin (Million US\$), 2014-2016

Figure 6-9: Global - Sales of Bronchitol (Million US\$), 2014-2016

Figure 7-1: Global – Cystic Fibrosis Therapeutics Market Breakup by Pharmacological Class (%), 2016

Figure 7-2: Global - CFTR Modulator Market for Cystic Fibrosis (Billion US\$), 2016-2022

Figure 7-3: Global - Mucolytic Agents Market for Cystic Fibrosis (Billion US\$), 2016-2022

Figure 7-4: Global - Pancreatic Enzyme Replacement Products Market for Cystic Fibrosis (Billion US\$), 2016-2022

Figure 7-5: Global – Antibiotics Market for Cystic Fibrosis (Billion US\$), 2016-2022

Figure 7-6: Global – Other Therapies Market for Cystic Fibrosis (Billion US\$), 2016-2022

Figure 8-1: Global – Cystic Fibrosis Therapeutics Market by Drug Molecule Type (%), 2016

Figure 8-2: Global - Small Molecule Market for Cystic Fibrosis (Billion US\$), 2016-2022

Figure 8-3: Global - Biologic Drugs Market for Cystic Fibrosis (Billion US\$), 2016-2022

Figure 9-1: Global - Cystic Fibrosis Therapeutics Market Breakup by CF Mutation Type (%), 2016

Figure 9-2: Global – Class I Gene Mutation Specific Therapy Market for Cystic Fibrosis (Billion US\$), 2016-2022

Figure 9-3: Prevalence of the F508del Mutation in Patients with Cystic Fibrosis (% of Patients with at Least 1 Allele)

Figure 9-4: Global – Class II Gene Mutation Specific Therapy Market for Cystic Fibrosis

(Billion US\$), 2016-2022

Figure 9-5: Global – Class III Mutation Specific Therapy Market for Cystic Fibrosis (Billion US\$), 2016-2022

Figure 10-1: Global - Cystic Fibrosis Therapeutics Market Breakup by Geography (%), 2016

Figure 10-2: North America - Cystic Fibrosis Therapeutics Market (Billion US\$), 2016-2022

Figure 10-3: Europe - Cystic Fibrosis Therapeutics Market (Billion US\$), 2016-2022

Figure 10-4: Asia-Pacific – Cystic Fibrosis Therapeutics Market (Billion US\$), 2016-2022

Figure 12-1: Global - Cystic Fibrosis Clinical Trials by Phase till June, 2017

Figure 12-2: Global - Cystic Fibrosis Clinical Trials by Key Players till June, 2017

Figure 12-3: Global – Cystic Fibrosis Clinical Trials by Countries till June, 2017

Figure 12-4: Global – Cystic Fibrosis Clinical Trials by Route of Administration till June, 2017

Figure 14-1: Global - Share of Major Players in Cystic Fibrosis Therapeutics Market (%), 2016

Figure 15-1: F. Hoffman La Roche Ltd. - Breakup of Revenue by Business Segments (%), 2016

Figure 15-2: F. Hoffmann-La Roche AG - Pharmaceuticals Division Revenue by Segments (%), 2016

Figure 15-3: F. Hoffmann-La Roche AG - Pharmaceuticals Division Revenue by Geography (%), 2016

Figure 15-4: Novartis - Sales by Business Segments (%), 2016

Figure 15-5: Novartis - Innovative Medicines Division Sales by Segments (%), 2016

Figure 15-6: Novartis - Pharmaceuticals Division Sales by Segments (%), 2016

Figure 15-7: Novartis - Sales by Geography (%), 2016

Figure 15-8: Vertex Pharmaceuticals Incorporated – Breakup of Revenue by Product (%), 2016

Figure 15-9: Vertex Pharmaceuticals Incorporated – Breakup of Revenue by Geography (%), 2016

Figure 15-10: Abbott Laboratories – Net Sales Breakup by Business Segments (%), 2016

Figure 15-11: Abbott Laboratories – Net Sales Breakup by Geography (%), 2016

Figure 15-12: Gilead Sciences, Inc. - Breakup of Revenue by Geographic Segments (%), 2016

Figure 15-13: Johnson & Johnson - Sales by Business Segments (%), 2016

Figure 15-14: Johnson & Johnson - Sales by Pharmaceutical Segments (%), 2016

Figure 15-15: Johnson & Johnson - Sales by Geography (%), 2016

Figure 15-16: Allergan plc - Breakup of Revenue by Business Segments (%), 2016

Figure 15-17: Allergan plc - Breakup of Revenue by Geography (%), 2016

Figure 15-18: GlaxoSmithKline plc - Breakup of Revenue by Business Segments (%), 2016

Figure 15-19: GlaxoSmithKline plc - Pharmaceuticals Division Revenue by Segments (%), 2016

Figure 15-20: GlaxoSmithKline plc - Breakup of Revenue by Geography (%), 2016

Figure 15-21: Mylan N.V. - Breakup of Revenue by Geographic Region (%), 2016

Figure 15-22: Pharmaxis Ltd - Breakup of Revenue by Business Segment (%), 2016

List Of Tables

LIST OF TABLES:

- Table 4 -1: Global - Key Cystic Fibrosis Drugs and Patent Expiry Status
- Table 12-1: Global – Cystic Fibrosis Products Pipeline Analysis
- Table 14-1: Global - Major Cystic Fibrosis Drugs
- Table 15-1: F. Hoffman La Roche Ltd. - Key Financials (Billion US\$), 2014-2016
- Table 15-2: Genentech, Inc. - Commercialized Cystic Fibrosis Product
- Table 15-3: Genentech, Inc. - Cystic Fibrosis Drugs in Pipeline
- Table 15-4: Novartis – Key Financials (Billion US\$), 2014-2016
- Table 15-5: Novartis - Commercialized Cystic Fibrosis Product
- Table 15-6: Novartis - Cystic Fibrosis Drugs in Pipeline
- Table 15-7: Vertex Pharmaceuticals Incorporated – Key Financials (Million US\$), 2014-2016
- Table 15-8: Vertex Pharmaceuticals Incorporated - Commercialized Cystic Fibrosis Product
- Table 15-9: Vertex Pharmaceuticals Incorporated - Cystic Fibrosis Drugs in Pipeline
- Table 15-10: Abbott Laboratories – Key Financials (Million US\$), 2014-2016
- Table 15-11: Abbott Laboratories - Commercialized Cystic Fibrosis Product
- Table 15-12: Gilead Sciences, Inc. - Key Financials (Billion US\$), 2014-2016
- Table 15-13: Gilead Sciences, Inc. - Commercialized Cystic Fibrosis Product
- Table 15-14: Gilead Sciences, Inc. – Cystic Fibrosis Drugs in Pipeline
- Table 15-15: Johnson & Johnson – Key Financials (Billion US\$), 2014-2016
- Table 15-16: Johnson & Johnson - Commercialized Cystic Fibrosis Product
- Table 15-17: Allergan plc - Key Financials (Million US\$), 2014-2016
- Table 15-18: Allergan plc - Commercialized Cystic Fibrosis Product
- Table 15-19: GlaxoSmithKline plc - Key Financials (Million US\$), 2014-2016
- Table 15-20: GlaxoSmithKline plc - Commercialized Cystic Fibrosis Product
- Table 15-21: GlaxoSmithKline plc – Cystic Fibrosis Drugs in Pipeline
- Table 15-22: Mylan N.V. - Key Financials (Million US\$), 2014-2016
- Table 15-23: Mylan N.V. - Commercialized Cystic Fibrosis Product
- Table 15-24: Pharmaxis Ltd - Key Financials (Million US\$), 2014-2016
- Table 15-25: Pharmaxis Ltd - Commercialized Cystic Fibrosis Product
- Table 15-26: Pharmaxis Ltd – Cystic Fibrosis Drugs in Pipeline

I would like to order

Product name: Global Cystic Fibrosis Therapeutics Market Outlook 2022

Product link: <https://marketpublishers.com/r/G9460E90A15EN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G9460E90A15EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970